COVID-19 та хронічна хвороба нирок: особливості лікування. Огляд літератури.

DOI: https://doi.org/10.31450/ukrjnd.2(74).2022.11
Ключові слова: хронічна хвороба нирок, COVID-19, статини, інгібітори ангіотензин-перетворюючого ферменту.

Анотація

Резюме. Метою цього дослідження було охарактеризувати особливості лікування пацієнтів із хронічною хворобою нирок та супутнім COVID-19. Проаналізовано статті, опубліковані у 2019-2021 роках в електронних базах PubMed, Scopus та Google Scholar.

У результаті цього огляду можна підсумувати наступні особливості лікування COVID-19 у хворих на хронічну хворобу нирок. Обов’язковим є продовження лікування інгібіторами ренін-ангіотензин-альдостеронової системи; важається, що лізиноприл використовується для уникнення підвищеної ниркової експресії ангіотензинперетворюючого ферменту 2. Спіронолактон може запобігти гострому ушкодженню легень і є доцільним у разі неефективності потрійної комбінації гіпотензивних лікарських засобів. Терапія низькими дозами розувастатину рекомендована пацієнтам із COVID-19 та хронічною хворобою нирок 3-5 стадії, які лікуються антиретровірусними засобами, такими як лопінавір та ритонавір, ремдесивір. Езетиміб доцільно застосовувати у разі неефективності високих доз статинів та з метою зниження ризику госпіталізації.

Завантаження

Дані завантаження ще не доступні.

Посилання

Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J Am Soc Nephrol. 2020;31(7):1380-1383. doi: 10.1681/ASN.2020040419.

McAdams M, Ostrosky-Frid M, Rajora N, Hedayati S. Effect of COVID-19 on Kidney Disease Incidence and Management. Kidney360. 2020;2(1):141-153. doi: 10.34067/KID.0006362020.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Donget L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97(5):829-838. doi: 10.1016/j.kint.2020.03.005.

Williamson EJ, WalkerAJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-436. doi: 10.1038/s41586-020-2521-4.

Podestà MA, Valli F, Galassi A, Cassiaa MA, Ciceri P, Barbieri L, et al. COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. Blood Purif. 2021;22:1-10. doi: 10.1159/000514467.

Farouk SS, Fiaccadori E, Cravedi P, Campbellet KN. COVID-19 and the kidney: what we think we know so far and what we don’t. J Nephrol. 2020;20:1-6. doi: 10.1007/s40620-020-00789-y.

Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020;52(6):1193-1194. doi: 10.1007/s11255-020-02451-9.

Ahmadian E, Khatibi SM, Soofiyani SR, Abediazar S, Shoja MM, Ardalan M, et al. Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms. Rev Med Virol. 2020:e2176. doi: 10.1002/rmv.2176.

Bitencourt  L, Pedrosa AL, Soares de Brito SBC, Fróes ACF, Tayná de Carvalho S, Fonseca GG, et al. COVID-19 and Renal Diseases: An Update. Curr Drug Targets. 2021;22(1):52-67. doi: 10.2174/1389450121999201013151300.

Albalate M, Arribas P, Torres E, Cintra M, Alcázar R, Puerta M,et al. Alta prevalencia de COVID 19 asintomático en hemodiálisis: aprendiendo dia a dia el primer mes de pandemia de COVID19. Nefrologia. 2020. doi: 10.1016/j.nefro.2020.04.005.

Ortiz A, Cozzolino M, Duivenvoorden R, Fliser D, Fouque D, Franssen CFM, et al. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation. 2021;36(1):87-94. doi: 10.1093/ndt/gfaa314.

Yang D, Xiao Y, Chen J, Chen Y, Luo P, Liu Q, et al. COVID-19 and chronic renal disease: clinical characteristics and prognosis. QJM. 2020;113(11):799-805. doi: 10.1093/qjmed/hcaa258.

Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M, et al. COVID-19 and the kidney: From epidemiology to clinical practice. J Clin Med. 2020;9(8):2506. doi: 10.3390/jcm9082506.

Collado S., Arenas M.D., Barbosa F., Cao H., Montero M.M., Villar-García J., et al. COVID-19 in Grade 4–5 Chronic Kidney Disease Patients. Kidney Blood Press Res 2020;45:768–774. doi: 10.1159/000511082.

Dudar I, Krasyuk E, Shymova A, Hryhorieva Y, Malasaiev M., Fierients O., et al. COVID-19 in patients with chronic kidney disease stage 5. Ukrainian Journal of Nephrology and Dialysis. 2021;2(70):38-47. doi: 10.31450/ukrjnd.2(70).2021.05.

Gevers S, Welink J, Nieuwkoop C. Remdesivir in COVID-19 Patients with Impaired Renal Function. JASN 2021;32(2):518-519. doi:10.1681/ASN.2020101535.

Adamsick ML, Gandhi RG, Bidell MR, Elshaboury RH, Bhattacharyya RP, Kim AY, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31(7):1384-1386. doi: 10.1681/ASN.2020050589.

Dashti-Khavidaki S, Khalili H, Nourian A. Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review. Iran J Kidney Dis. 2020 Jul;14(4):247-255.

2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33):3021–3104 doi: /10.1093/eurheartj/ehy339.

Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526:135‐140. doi: 10.1016/j.bbrc.2020.03.044.

Wan Y, Shang J, Graham R, Baric RS, Liet F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020;94(7):e00127-20. doi: 10.1128/JVI.00127-20.

Hakeam HA, Alsemari M, Duhailib ZA, Ghonem L, Alharbi SA, Almutairy E, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: a multicenter, prospective study. J Cardiovasc Pharmacol Ther. 2021;26(3):244-252. doi: 10.1177/1074248420976279.

Gilstrap LG, Fonarow GC, Desai AS, Liang L, Matsouaka R, DeVore AD, et al. Initiation, continuation, or withdrawal of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc. 2017;6:e004675. doi: 10.1161/JAHA.116.004675.     

Nicin L, Abplanalp WT. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41:1804-1806. doi: 10.1093/eurheartj/ehaa311.

Tetlow S, Segiet-Swiecicka A, O'Sullivan R, O’Halloran S, Kalb K, Brathwaite-Shirley C, et al. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J Intern Med. 2021;289(5):688-699. doi: 10.1111/joim.13202.

Diaz JH. Hypothesis: angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID‐19. J Travel Med. 2020;27(3): taaa041. doi: 10.1093/jtm/taaa041.

Kamyshnyi A, Krynytska I, Matskevych V, Marushchak M, Lushchak O. Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology. Int J Hypertens. 2020;2020:8019360. doi: 10.1155/2020/8019360.

Korol L, Stepanova N, Vasylchenko V, Snisar L, Lebid L, Kolesnyk, M. Plasma oxalic acid as a trigger for oxidative processes in end-stage renal disease patients. Ukrainian J Nephrol Dialysis. 2021;1(69):46-53. doi: 10.31450/ukrjnd.1(69).2021.07.

Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21-38. doi: 10.1016/j.phrs.2017.06.005.

Fang L, Karakiulakis G, Rotha M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8.

Reynolds HR, Adhikari S, Pulgarin C. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. 2020;382:2441–2448. doi: 10.1056/NEJMoa2008975.

Mancia G, Rea F, Ludergnani M, Apolone G, Corraoet G, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N. Engl. J. Med. 2020;382:2431–2440. doi: 10.1056/NEJMoa2006923.

Zhang J, Wang M, Ding W, Wan G. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Life Sci. 2020Sep15;257:118142. doi: 10.1016/j.lfs.2020.118142.

Teslyk T, Yarmolenko O, Bumeister V, Demikhova N, Prykhodko O, Dmytruk S, et al. The remodeling of lungs under the influence of alloxan-induced hyperglycemia. Romanian Journal of Diabetes, Nutrition and Metabolic Diseases. 2020;27(1):45-49. doi: 10.46389/rjd-2020-1008.

Yarmolenko O, Bumeister V, Polak S, Gordienko O, Prykhodko O, Demikhova N, Shkatula Yu, et al. The effect of the experimental chronic hyperglycemia on the kidney and myocardium. Ukr J Nephr Dial. 2021;3(71):3-10. doi: 10.31450/ukrjnd.3(71).2021.01.

Degen A, Krynytska I, Kamyshnyi A. Changes in the transcriptional activity of the entero-insular axis genes in streptozotocin-induced diabetes and after the administration of TNF-α non-selective blockers. Endocr. Regul. 2020;54(3):160-71. doi: 10.2478/enr-2020-0019.

Demikhova N, Cherkashyna L, Chernatska O, Mazur T, Aleksakhina T, Demikhov O. The relationship between lipid metabolism and albuminuration level with single nucleotide polymorphism -204a>c [rs 3808607] CYP7A1 gene in patients with 2 type diabetes mellitus and diabetic nephropathy. Romanian Journal of Diabetes, Nutrition and Metabolic Diseases. 2019;26(3):253-261. doi: 10.2478/rjdnmd-2019-0026.

Wang W, Song A, Zeng Y. Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity. BMC Cardiovasc. Disord. 2018;18:133. doi: 10.1186/s12872-018-0875-4.

Agata J, Ura N, Yoshida H. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens. Res. 2006;29:865-874. doi: 10.1291/hypres.29.865.

Callera GE, Antunes TT, Correa JW. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis. Biosci. Rep. 2016;36(5):e00398. doi: 10.1042/BSR20160344.

Kidoguchi S, Sugano N, Takane K, Takahashi Y, Morisawa N, Yarita M, et al. Azilsartan causes natriuresis due to its sympatholytic action in kidney disease. Hypertens Res. 2019;42(10):1507-1517. doi: 10.1038/s41440-019-0271-1.

Hamming I, van Goor H, Turner AJ. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp. Physiol. 2008;93:631-638. doi: 10.1113/expphysiol.2007.041855.

Demikhov O, Dehtyarova I, Rud O, Khotyeev Y, Larysa K, Cherkashyna L et al.  Arterial hypertension prevention as an actual medical and social problem. Bangladesh Journal of Medical Science. 2020;19(4):722-729. doi: 10.3329/bjms.v19i4.46632.

Cadegiani FA, Goren A, Wambierb CG. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020Oct;143:110112. doi: 10.1016/j.mehy.2020.110112.

Lima Martínez MM, Contreras MA, Marín W, D’Marco L. Statins in COVID-19: is there any foundation? Clin Investig Arterioscler. 2020;32(6):278-281.  doi: 10.1016/j.arteri.2020.06.003.

Stepanova  N,  Rysyev  A,  Rusyn  O,  Ostapenko  T,  Snisar  L,  Kompaniets  O,  et al.  High-density  lipoproteins  and  clinical  outcomes  of  COVID-19  in  hemodialysis  patients:  A  multicenter,  propensity-score  matched  case-control  study Ukr J Nephr Dial. 2022;1(73):22-30. doi: 10.31450/ukrjnd.1(73).2022.03.

Mazur T, Demikhova N,  Rudenko  T, Yurchenko  A,  Yezhova  O,  Bokova  S. Chronic inflammation and progression of chronic kidney disease in patients with type 2 diabetes. Ukr J Nephr Dial. 2021;4(72):36-43. doi: 10.31450/ukrjnd.4(72).2021.05.

Karalis DG. Are statins safe in patients with COVID-19? J Clin Lipidol. 2020 Jul-Aug;14(4):396-397. doi: 10.1016/j.jacl.2020.06.009.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-188.doi: 10.1093/eurheartj/ehz455.

Chernatska O, Demikhova N, Rudenko T, Demikhov A. Assesment of the lipid profile correction in patients with arterial hypertension and type 2 diabetes mellitus. Azerbaijan Medical Journal. 2019;1:95-99.

Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. Int J Infect Dis. 2020 Jul;96:615-617. doi: 10.1016/j.ijid.2020.05.115.

De Spiegeleer A, Bronselaer A, Teo JT, Bean D, Fedson D, De Spiegeleer B, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J. Am. Med. Dir. Assoc. 2020;21:909–914. doi: 10.1016/j.jamda.2020.06.018.

Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020;313:126–136. doi: 10.1016/j.atherosclerosis.2020.09.008.

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–2371.doi: 10.1016/j.jacc.2020.03.031.

Israel A, Schaffer A, Cicurel A, Cheng K, Sinha S, Schiff E, et al. Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population. Elife. 2021Jul27;10:e68165.  doi: 10.7554/eLife.68165.

Krynytska I, Marushchak M, Birchenko I, Dovgalyuk A, Tokarskyy O. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review). Iran J Microbiol. 2021 Dec;13(6):737-747. doi: 10.18502/ijm.v13i6.8072.

Introduction: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S1-S2. doi: 10.2337/dc21-Sint.

Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. Int J Clin Pract. 2021;75(6):e14124. doi: 10.1111/ijcp.14124.

Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine. 2021;37:100957. doi: 10.1016/j.eclinm.2021.100957.

Nejat R, Sadr AS. Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. In Silico Pharmacol. 2020;9(1):1. doi: 10.1007/s40203-020-00058-7.

Rothlin RP, Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli HM, et al. Angiotensin Receptor Blockers for COVID-19: pathophysiological and pharmacological considerations about ongoing and future prospective clinical trials. Front Pharmacol. 2021;12:603736. doi: 10.3389/fphar.2021.603736.

Ligt M, Hesselink MKC, Jorgensen J, Jocken JWE, Blaak EE, Goossens GH et al. The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Obesity (Silver Spring). 2021;29(9):1423-1426. doi: 10.1002/oby.23221.

Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A, et al. Comorbidity Assessment Is Essential During COVID-19 Treatment. Front Physiol. 2020;11:984. doi: 10.3389/fphys.2020.00984.


Переглядів анотації: 555
Завантажень PDF: 19236
Опубліковано
2022-06-06
Як цитувати
Chernatska, O., & Grek, A. (2022). COVID-19 та хронічна хвороба нирок: особливості лікування. Огляд літератури. Український Журнал Нефрології та Діалізу, (2(74), 83-89. https://doi.org/10.31450/ukrjnd.2(74).2022.11
Номер
№ 2(74) (2022): Ukrainian Journal of Nephrology and Dialysis
Розділ
Школа нефролога
Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.